EGFR and neoplasm: When a tumor is at an advanced stage, molecular pathogenesis has progressed to a level where there are numerous genetic and epigenetic changes, allowing cancer cells to be naturally resistant or to rapidly develop resistance to treatments, even to the new targeted tyrosine kinase inhibitors such as that for EGFR [2].